Two patients with chronic mucocutaneous candidiasis caused by TRAF3IP2 deficiency

Samantha Shafer,Yikun Yao,William Comrie,Sarah Cook,Yu Zhang,Gözde Yesil,Elif Karakoç-Aydiner,Safa Baris,Haluk Cokugras,Sezin Aydemir,Ayca Kiykim,Ahmet Ozen,Michael Lenardo
DOI: https://doi.org/10.1016/j.jaci.2020.12.629
IF: 14.29
2021-07-01
Journal of Allergy and Clinical Immunology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>TRAF3 interacting protein 2 (TRAF3IP2) (Act1) is an adapter protein that interacts with IL-17R via its similar expression to fibroblast growth factor genes and IL-17R domain and coordinates 2 separate proinflammatory pathways following IL-17 cytokine stimulation.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>We sought to elucidate the immunologic consequences of TRAF3IP2 homozygous mutations to improve treatments for immunodeficiency patients with chronic mucocutaneous candidiasis.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We describe 2 patients presenting with chronic mucocutaneous candidiasis who harbor biallelic nonsense mutations in TRAF3IP2. The cellular and molecular features of this genetic defect were assessed using <em>in vitro</em> cytokine assays and protein analysis.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>We show that the homozygous mutation causes complete loss of protein expression. We also show that the absence of TRAF3IP2 was associated with a defective response to combined IL-2/IL-25 (IL-17E) stimulation.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Failure to initiate normal signaling downstream of IL-17R engagement likely contributes to the patients' recurrent fungal infections. These findings add to our molecular understanding of genetic defects affecting this critical pathway of antifungal immunity.</p>
immunology,allergy
What problem does this paper attempt to address?